Atlas Trials

Recurrent Mixed Phenotype Acute Leukemia

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Mixed Phenotype Acute Leukemia

RecordFirmDate
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966)Fred Hutchinson Cancer Center2019-07-10
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)Fred Hutchinson Cancer Center2018-02-23
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193)M.D. Anderson Cancer Center2018-01-18
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (NCT02879695)National Cancer Institute (NCI)2017-10-25
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034)Fred Hutchinson Cancer Center2017-10-24
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (NCT02135874)M.D. Anderson Cancer Center2014-10-27

Track Recurrent Mixed Phenotype Acute Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.